iCAD, Inc. (NASDAQ:ICAD) Holdings Decreased by Renaissance Technologies LLC

Renaissance Technologies LLC cut its position in shares of iCAD, Inc. (NASDAQ:ICAD) by 20.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 475,593 shares of the technology company’s stock after selling 125,697 shares during the quarter. Renaissance Technologies LLC owned 1.79% of iCAD worth $870,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ICAD. First Eagle Investment Management LLC raised its holdings in shares of iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after purchasing an additional 41,000 shares during the period. Geode Capital Management LLC raised its stake in iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after acquiring an additional 17,059 shares during the period. Perritt Capital Management Inc lifted its holdings in iCAD by 1.9% in the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after acquiring an additional 3,600 shares during the last quarter. Summit Trail Advisors LLC acquired a new position in iCAD in the fourth quarter valued at approximately $214,000. Finally, Wells Fargo & Company MN grew its holdings in shares of iCAD by 51.3% during the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after purchasing an additional 13,402 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ICAD shares. Craig Hallum downgraded iCAD from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th. StockNews.com assumed coverage on iCAD in a research note on Saturday, April 26th. They issued a “sell” rating on the stock. BTIG Research lowered shares of iCAD from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 16th. Finally, Laidlaw reiterated a “hold” rating on shares of iCAD in a research report on Thursday, April 17th.

iCAD Price Performance

Shares of ICAD stock opened at $3.42 on Friday. iCAD, Inc. has a 12-month low of $1.18 and a 12-month high of $3.78. The firm has a market capitalization of $93.59 million, a price-to-earnings ratio of -26.31 and a beta of 1.78. The business has a 50 day simple moving average of $2.38 and a 200 day simple moving average of $2.25.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The company had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.